Anti-VEGF Therapies in the Clinic
Anti-VEGF Therapies in the Clinic
复制标题
DOI：
10.1101/cshperspect.a006577
复制
发表时间：
2012-10-01
影响因子：
5.4
通讯作者：
Hurwitz, Herbert I.
中科院分区：
文献类型：
--
作者：
Meadows, Kellen L.;Hurwitz, Herbert I.
抗血管生成药物的开发和使用，特别是那些针对血管内皮生长因子（VEGF）的药物，已经成为许多肿瘤类型抗癌方案的一个组成部分。本综述旨在强调抗vegf治疗的一些最重要的临床成功和失败，并在可能的情况下提出已经吸取的重要教训。本综述强调来自FDA批准和/或已完成III期研究的药物的数据。
The development and use of antiangiogenesis agents, particularly those targeting vascular endothelial growth factor (VEGF), has become an integral component of anticancer regimens for many tumor types. This review is intended to highlight some of the most important clinical successes and failures of anti-VEGF therapies, and where possible, to suggest important lessons that have been learned. This review emphasizes data from agents that have been FDA approved and/or have completed phase III studies.